Profound Medical to roll out Tulsa-AI BPH module

Executive Summary

• Profound Medical Corp. is launching its Tulsa-AI volume reduction module for treating benign prostatic hyperplasia (BPH) at the RSNA meeting (Nov 30–Dec 4) and presenting new clinical data for Tulsa-Pro in prostate cancer at both RSNA and the Society for Urologic Oncology (SUO) meeting (Dec 2–5).
• The new AI-powered module allows physicians to stack multiple prostate cases in a single day using existing hardware and reimbursement codes, aiming to streamline workflow and reduce procedure times.
• CEO Arun Menawat states that the reduced procedure times are expected to triple the total available market for prostate disease treatments to approximately 600,000 patients annually.

Key Details

• Product Launch: Tulsa-AI volume reduction module for BPH treatment.
• Event Schedule:
  • RSNA (Chicago): Nov 30 to Dec 4. Profound will be at booth No. 3153, South Hall A.
  • SUO (Phoenix): Dec 2 to Dec 5.
• Market Impact: CEO expects the AI module to increase adoption and triple the total available market to ~600,000 patients annually.
• Clinical Presentations & Sessions:
  • RSNA (Monday, Dec 1, 12:15 p.m. CST): "Captain Randomized Controlled Trial of MRI-Guided Transurethral Ultrasound Ablation (Tulsa) Versus Robotic Radical Prostatectomy" by Dr. Pejman Ghanouni (Stanford).
  • RSNA (Tuesday, Dec 2, 11:30 a.m. CST): "Discover Tulsa-Pro: AI-powered MRI-guided Precision Prostate Ablation" by Dr. Daniel Costa (MD Anderson) and Dr. Joseph Busch (The Busch Center).
  • RSNA (Tuesday, Dec 2, 1:30 p.m. CST): "MR-guided transurethral ultrasound ablation (Tulsa): single center outcomes in 160 patients with organ-confined prostate cancer" by Dr. Joseph Busch.
  • SUO (Friday, Dec 5, 2:30 p.m. MST): "Randomized Controlled Trial evaluating MRI-Guided Transurethral Ultrasound Ablation (Tulsa) Versus Robotic Prostatectomy" by Dr. Geoffrey Sonn (Stanford).
• On-Demand Content: Educational presentations available on Tulsa for prostate cancer, including pre-treatment planning and post-treatment assessment.
• Company Background: Profound is a commercial-stage medical device company developing AI-powered, MRI-guided, incision-free therapies. Tulsa-Pro is CE marked, Health Canada approved, and FDA 510(k) cleared. Sonalleve is also commercialized for uterine fibroids and other indications.

Notable Quotes

• "We're confident to launch the Tulsa-AI volume reduction module for BPH, following a successful pilot trial earlier this year... We expect the reduced procedure times will increase adoption of the Tulsa procedure and triple Profound's total available market in prostate disease to about 600,000 patients annually." — Arun Menawat, CEO and Chairman